%0 Journal Article %T Can the response to mood stabilizers be predicted in bipolar disorder? %+ Institut Mondor de Recherche Biomédicale (IMRB) %+ Service de psychiatrie %+ Pôle de Psychiatrie [Lille] %+ Fondation FondaMental [Créteil] %+ Pôle de psychiatrie %A Geoffroy, Pierre Alexis %A Bellivier, Frank %A Leboyer, Marion %A Etain, Bruno %Z P.A. Geoffroy has received a prize from Bayer for being Laureate of the medical university of Lille. F. Bellivier has r eceived honoraria and financial support as an independent symposium speaker from Sanofi - Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol - Myers Squibb and Servier. M. Leboyer has received honoraria and financial support as an independent symposium speaker from AstraZeneca and Servier. B. Etain has received honoraria and financial support as an independent symposium speaker from Sanofi - Aventis, Lundbeck, AstraZeneca, Eli Lilly, Bristol - Myers Squibb and Servier. %< avec comité de lecture %J Front Biosci (Elite Ed) %V 6 %P 120-38 %8 2014 %D 2014 %M 24389147 %Z Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthJournal articles %X Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for the development of personalized therapies. %G English %2 https://inserm.hal.science/inserm-00950859/document %2 https://inserm.hal.science/inserm-00950859/file/Geoffroy-Bellivier-Leboyer-Etain_2014_Can_the_response_to_mood_stabilizers_be_predicted_in_BD_HAL.pdf %L inserm-00950859 %U https://inserm.hal.science/inserm-00950859 %~ INSERM %~ UNIV-PARIS7 %~ APHP %~ IMRB %~ UPEC %~ UNIV-PARIS